← Leaderboards
Jianxun Jim Song
University Of Kentucky
$6,323,672
Attributed
$8,656,606
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,656,606 · 8
By mechanism
R01$7,150,206 · 4
R21$1,271,984 · 3
K18$234,416 · 1
Top collaborators
- Jin-Ming Yang8 shared
- Thomas A Ficht1 shared
Others in their field
Top investigators on “Innovation”
- David R. Weir · University Of Michigan At Ann Arbor$382,307,654
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$319,874,172
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$311,654,401
- Richard A Gibbs · Baylor College Of Medicine$300,634,418
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$271,752,220
Research focus
InnovationT-LymphocyteIn VitroLaboratoriesPublishingAntigensCytotoxic T-LymphocytesCellsAdoptive Cell TransfersRegulatory T-LymphocyteImmunotherapyImmunePluripotent Stem CellsTumorSignal TransductionMediatingIn VivoInsightRegulationCytokineGenesCd8b1 GeneNeoplastic CellMelanoma
Grant awards (23)
Integrative Targeted Therapy for Melanoma$608,620
R01 · FY2025 · CA
Integrative Targeted Therapy for Melanoma$632,195
R01 · FY2024 · CA
Combating melanoma with an attenuated bacterial therapeutic$591,249
R01 · FY2024 · CA · contact PI
Combating melanoma with an attenuated bacterial therapeutic$621,545
R01 · FY2023 · CA · contact PI
Nucleus Accumbens-Associated Protein-1 in Melanoma Immunotherapy$550,644
R01 · FY2023 · CA
Combating chronic neuroinflammatory disorders by targeting NAC1$187,305
R21 · FY2023 · AI · contact PI
Nucleus Accumbens-Associated Protein-1 in Melanoma Immunotherapy$550,643
R01 · FY2022 · CA
Combating chronic neuroinflammatory disorders by targeting NAC1$225,279
R21 · FY2022 · AI · contact PI
Nucleus Accumbens-Associated Protein-1 in Melanoma Immunotherapy$561,881
R01 · FY2021 · CA
Nucleus Accumbens-Associated Protein-1 in Melanoma Immunotherapy$562,597
R01 · FY2020 · CA
Stem cell-derived regulatory T cells for therapeutic use in arthritis$373,001
R01 · FY2020 · AI · contact PI
Stem cell-derived regulatory T cells for therapeutic use in arthritis$373,001
R01 · FY2019 · AI · contact PI
Nucleus Accumbens-Associated Protein-1 in Melanoma Immunotherapy$417,630
R01 · FY2018 · CA
Stem cell-derived regulatory T cells for therapeutic use in arthritis$385,126
R01 · FY2018 · AI · contact PI
Role of stem cell-derived T lymphocytes in chronic HBV infection$185,625
R21 · FY2018 · AI · contact PI
Nucleus Accumbens-Associated Protein-1 in Melanoma Immunotherapy$160,114
R01 · FY2018 · CA
Stem cell-derived regulatory T cells for therapeutic use in arthritis$384,529
R01 · FY2017 · AI · contact PI
Role of stem cell-derived T lymphocytes in chronic HBV infection$232,950
R21 · FY2017 · AI · contact PI
Stem cell-derived regulatory T cells for therapeutic use in arthritis$377,431
R01 · FY2016 · AI · contact PI
Directed differentiation of HBV-specific CTL from iPSC for cell-based therapies$200,375
R21 · FY2015 · AI · contact PI
Directed differentiation of HBV-specific CTL from iPSC for cell-based therapies$240,450
R21 · FY2014 · AI · contact PI
Impact of Highly Active T Lymphocytes from Induced Pluripotent Stem Cells$117,208
K18 · FY2012 · CA · contact PI
Impact of Highly Active T Lymphocytes from Induced Pluripotent Stem Cells$117,208
K18 · FY2011 · CA · contact PI